Urologix March Stock Price Gain Propelled By BPH Systems, Disposables
This article was originally published in The Gray Sheet
Executive SummaryIncreased market penetration and improved reimbursement rates for Urologix, Inc.'s Targis Cooled ThermoTherapy system for treatment of benign prostatic hyperplasia (BPH) translated into a nearly 30% stock price gain in March. The issue advanced $4.17 to close at $18.17 for the month
You may also be interested in...
TTS Pharma CEO Mark Tucker discusses his ambition to bring a legal CBD oil to the UK market, following the recent submission of a European Union novel food application.